secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-03-16T23:59:59+00:00
Accession:  0001193125-22-077264
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics CFO Steve Krognes to join Board; COO Alex Schuth adds CFO role effective May 1, 2022
--------------------------------------------------------------------------------

- Krognes transitions from CFO to Class III director as of May 1, 2022; his term expires at 2023 annual meeting.
- Alexander Schuth, current COO and Secretary, becomes Chief Operating and Financial Officer on May 1, 2022.
- No changes to Schuth's compensation in connection with his expanded role; Krognes to receive standard board cash and equity.
- Krognes cited a personal desire to move back to Europe; Watts and Board expressed gratitude and support for continuity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/d310285d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-077264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer